Sanofi
Sanofi – aiming for number one in the world’s biggest diabetes market
December 18, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, Sanofi, diabetes, obesity
Sanofi is no different from any other major pharma company in seeing China as the single most important growth market …
CHMP turns down Kynamro
December 17, 2012Sales and Marketing CHMP, Genzyme, Kynamro, Sanofi
Genzyme has expressed frustration at the CHMP’s negative opinion of its novel drug Kynamro, and plans to ask it to …
Working Life: Caroline Horwood
December 6, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Working Life
How did you find your way into your current role?Through an exciting and challenging route over 25 years! The key …
Pharmacos ink green manufacturing pact with EU academics
December 3, 2012Manufacturing and Production Bayer, EU, Pharmacos, Sanofi
A group of top pharma multinationals have set up a public-private partnership dedicated to the development of manufacturing sustainable pharmaceuticals …
European nod for Sanofi drugs
November 19, 2012Research and Development, Sales and Marketing CHMP, Sanofi
Two of Sanofi’s key drugs have cleared the penultimate hurdle to approval in Europe with a recommendation from the CHMP. …
Sanofi appoints Gary Nabel as chief scientific officer
November 16, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Nabel, Sanofi
Sanofi has announced the appointment of Dr Gary Nabel, senior VP, chief scientific officer and deputy to the president for …
Regeneron to invest $70m in NYC manufacturing
November 15, 2012Manufacturing and Production NY, Regeneron, Sanofi, US
Regeneron has confirmed it will invest almost $70 million to expand its manufacturing in New York City in a move …
Sanofi’s chief executive new president elect of EFPIA
November 7, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chris Viehbacher, Sanofi
European pharma members body the EFPIA has announced that Sanofi’s chief executive Christopher Viehbacher is to stand as its new …
Sanofi criticised for multiple sclerosis manoeuvres
November 2, 2012Sales and Marketing Cancer, Lemtrada, MS, Sanofi
Sanofi is facing a backlash as it prepares its new MS treatment for the market. Lemtrada (alemtuzumab) has produced very …
Diabetes softens generics blow for Sanofi
October 30, 2012Sales and Marketing Eloxatin, Plavix, Sanofi, diabetes, emerging markets, patent cliff
Sanofi has unveiled its results for the third quarter, with news that the damage done by patent expiries has not …
FDA committee recommends Kynamro
October 23, 2012Research and Development, Sales and Marketing FDA, Genzyme, Kynamro, Sanofi
Sanofi’s anti-cholestrol drug Kynamro has been recommended by an FDA committee, paving the way for US approval early next year. …
Sanofi’s Zaltrap data published
October 8, 2012Research and Development, Sales and Marketing Erbitux, Sanofi, Stivarga, Zaltrap, avastin
Detailed data from the Phase III trial of Sanofi’s newly-licenced anti-VEGF cancer drug Zaltrap, co-marketed with Regeneron, has been published. …
Sanofi acquires leading Colombian firm
October 4, 2012Sales and Marketing Columbia, Genfar, Latin America, Sanofi
Sanofi is expanding its presence in Latin American with the acquisition of a Colombian pharma company. Genfar is headquartered in …
Patent losses force change for Sanofi
October 3, 2012Sales and Marketing Avapro, BMS, Plavix, Sanofi, patent loss
Patent expiries are behind the decision by Sanofi and Bristol-Myers Squibb to radically restructure their long-term corporate alliance. The loss …
Quality issues prompt Sanofi typhoid vaccine recall
October 3, 2012Manufacturing and Production Sanofi, Typhen Vi, recall
Sanofi has recalled several lots of its typhoid fever vaccine Typhim Vi on fears that a quality defect could compromise …
Latest content
Five Facts about cardiovascular disease
